Donor-Derived CAR-T Cell Therapy
Time: 11:30 am
day: Day 1: Pre-Clinical & Translational - Morning
Details:
- Allo-SCT is a curative treatment option for high-risk leukemias. However, pts who progress after allo-SCT have limited treatment options.
- One potential solution is to use their healthy donors’ T cells to make CAR-Ts. This approach not only enables pts who would otherwise be ineligible for CAR-T cell therapy, but may also provide healthier CAR-T cells for better clinical outcome
- We will share the scientific concepts and preliminary clinical data demonstrating clinical proof of concept of this approach
